Drugs / Prometic Immune Globulin Intravenous
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02269163 | Jan 2016 → Jan 2019 | immunodeficiency disease | Prometic Biotherapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prometic Immune Globulin Intravenous | “Liquid formulation of Prometic Immune Globulin Intravenous 10% (human) in 50 mL vials containing 100 mg/mL of immunoglobulin G (IgG)” NCT02269163 ↗ |
| Route | Intravenous | “Prometic Immune Globulin Intravenous 10%” NCT02269163 ↗ |